Showing results (71-80 of 186) with videos related to
Sort By:
Pageof 19
Frontiers in Pharmacology|April 25, 2022
Assessing the Consequences of External Reference Pricing for Global Access to Medicines and Innovation: Economic Analysis and Policy ImplicationsAndrás Incze, Zoltán Kaló, Jaime Espín, et al.Cardiovascular Revascularization Medicine : Including Molecular Interventions|December 27, 2016
Cost-effectiveness analysis of the orbital atherectomy system: Two-year follow-upLouis P Garrison, Marita R Zimmermann, Christopher H Young, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 1, 2025
Evolving Concept of Value in Health Economics and Outcomes Research: Emerging Tools for Innovation and Access to Cell and Gene Therapies for Rare DiseasesWalter Toro, Min Yang, Anish Patel, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2007
Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force reportLouis P Garrison, Peter J Neumann, Pennifer Erickson, et al.Vaccines|May 25, 2017
The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United StatesBlythe J S Adamson, Josh J Carlson, James G Kublin, et al.Pharmacoeconomics|June 9, 2023
Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key DriversAurelie Meunier, Louise Longworth, Manuel Gomes, et al.Journal of Managed Care & Specialty Pharmacy|August 3, 2015
Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT)William J Canestaro, Daryl E Pritchard, Louis P Garrison, et al.Cancer|June 27, 2007
Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancerLouis P Garrison, Deborah Lubeck, Deepa Lalla, et al.Applied Health Economics and Health Policy|March 26, 2014
Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturersJosh J Carlson, Katharine S Gries, Kai Yeung, et al.Rheumatology and Therapy|January 14, 2017
Estimating the Cost of Illness of Giant Cell Arteritis in the United StatesJoseph B Babigumira, Meng Li, Denise M Boudreau, et al.Pageof 19